Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Controller | March 13, 2020 | March 13, 2020 |
| Valion Bio, Inc.TIVC · Entity 8459 | Chief Financial Officer | April 01, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date March 13, 2020 · Filed March 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,353 |
Reported balance
After 2020-03-13 transaction · row 1
1 source rowRow 1 · 2020-03-13 · Purchase · Acquired 2,000 · Balance 7,353 |
Valion Bio, Inc.
Report date April 01, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2032-03-31 | Direct | 117,880 |
Reported balance
After 2022-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-01 · Grant · Acquired 117,880 · Balance 117,880 F1: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the 36 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the 36 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2022 Filed Apr 5, 2022 17:15 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 117,880 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001104659-22-042855 · tm2211723d2_4.xml · derivative · entry 1 Cai Veronica · CIK 0001801322 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,880 Underlying: Common Stock · 117,880 shares Expires 2032-03-31 F1 · derivative.exercise_date: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the 36 months thereafter. Read SEC document |
| March 13, 2020 Filed Mar 13, 2020 22:55 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 2,000 | $4.11 | $8,220.00 |
DisclosureSEC source: 0001209191-20-019037 · doc4.xml · nonDerivative · entry 1 Cai Veronica · CIK 0001801322 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,353 Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 01:27 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,678 | $6.23 | $10,453.94 |
DisclosureSEC source: 0001209191-20-009039 · doc4.xml · nonDerivative · entry 1 Cai Veronica · CIK 0001801322 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,353 F1 · shares: Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan ("ESPP") on February 10, 2020. Read SEC document |
| January 23, 2020 Filed Jan 28, 2020 00:54 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $6.85 | $0.00 |
DisclosureSEC source: 0001209191-20-005064 · doc4.xml · derivative · entry 1 Cai Veronica · CIK 0001801322 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The grant vests monthly for four years from date of grant. Read SEC document |
| September 16, 2019 Filed Jan 28, 2020 00:54 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001209191-20-005063 · doc4.xml · derivative · entry 1 Cai Veronica · CIK 0001801322 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2029-09-16 F1 · derivative.exercise_date: Award vests over a four (4) year period on each monthly anniversary commencing September 3, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.